BACKGROUND: Concomitant systemic and intracatheter antibiotic therapy is a therapeutic option for catheter-related bloodstream infections (CRBSI) in patient fitted with long-term intravenous central catheters. CRBSI are mainly caused by Gram-positive bacteria. Daptomycin (DPT) is an antibiotic active against Gram-positive bacteria with high bactericidal activity and good biofilm penetration. OBJECTIVE: To study the efficacy of DPT given systemically and as lock therapy in the treatment of CRBSI. MATERIALS AND METHODS: A retrospective review was conducted of adult patients with a long-term central venous catheter (CVC) receiving both systemic intravenous and intracatheter lock therapy for CRBSI. The primary outcome was catheter maintenance, following clinical success and microbiological eradication. RESULTS: Eight patients who had failed previous standard therapy (vancomycin 7, cefazolin 1) were included in the study. In all but one, coagulase-negative staphylococci were repeatedly isolated. The other patient had enterococcal infection. DPT, given intravenously and as lock therapy, was successful in six of eight cases. The mean time to negative blood cultures was 2 days (range 1-6). In two cases neither clinical nor microbiological response was documented and the catheter was removed. DISCUSSION: Systemic and intracatheter therapy with DPT is feasible, carries no toxicity and is apparently effective. DPT might be a suitable therapeutic option in CRBSI to achieve CVC sterilization and preserve the catheter.
BACKGROUND: Concomitant systemic and intracatheter antibiotic therapy is a therapeutic option for catheter-related bloodstream infections (CRBSI) in patient fitted with long-term intravenous central catheters. CRBSI are mainly caused by Gram-positive bacteria. Daptomycin (DPT) is an antibiotic active against Gram-positive bacteria with high bactericidal activity and good biofilm penetration. OBJECTIVE: To study the efficacy of DPT given systemically and as lock therapy in the treatment of CRBSI. MATERIALS AND METHODS: A retrospective review was conducted of adult patients with a long-term central venous catheter (CVC) receiving both systemic intravenous and intracatheter lock therapy for CRBSI. The primary outcome was catheter maintenance, following clinical success and microbiological eradication. RESULTS: Eight patients who had failed previous standard therapy (vancomycin 7, cefazolin 1) were included in the study. In all but one, coagulase-negative staphylococci were repeatedly isolated. The other patient had enterococcal infection. DPT, given intravenously and as lock therapy, was successful in six of eight cases. The mean time to negative blood cultures was 2 days (range 1-6). In two cases neither clinical nor microbiological response was documented and the catheter was removed. DISCUSSION: Systemic and intracatheter therapy with DPT is feasible, carries no toxicity and is apparently effective. DPT might be a suitable therapeutic option in CRBSI to achieve CVC sterilization and preserve the catheter.
Authors: Anne-Marie Chaftari; Ray Hachem; Victor Mulanovich; Roy F Chemaly; Javier Adachi; Kalen Jacobson; Ying Jiang; Issam Raad Journal: Int J Antimicrob Agents Date: 2010-05-08 Impact factor: 5.283
Authors: Peter Pronovost; Dale Needham; Sean Berenholtz; David Sinopoli; Haitao Chu; Sara Cosgrove; Bryan Sexton; Robert Hyzy; Robert Welsh; Gary Roth; Joseph Bander; John Kepros; Christine Goeschel Journal: N Engl J Med Date: 2006-12-28 Impact factor: 91.245
Authors: Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint Journal: Clin Infect Dis Date: 2011-04-01 Impact factor: 9.079
Authors: J L Del Pozo; R Rodil; A Aguinaga; J R Yuste; C Bustos; A Montero; G Espinosa; N García-Fernández Journal: Int J Clin Pract Date: 2012-03 Impact factor: 2.503
Authors: Stijn I Blot; Pieter Depuydt; Lieven Annemans; Dominique Benoit; Eric Hoste; Jan J De Waele; Johan Decruyenaere; Dirk Vogelaers; Francis Colardyn; Koenraad H Vandewoude Journal: Clin Infect Dis Date: 2005-10-25 Impact factor: 9.079
Authors: P Brandon Bookstaver; John C Williamson; Brian Keith Tucker; Issam I Raad; Robert J Sherertz Journal: Ann Pharmacother Date: 2009-02-03 Impact factor: 3.154
Authors: Benito Almirante; Joan Gavaldà; Jana Basas; Marta Palau; Carlos Ratia; José L Del Pozo; María Teresa Martín-Gómez; Xavier Gomis; Eduard Torrents Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191